Interferon-gamma Inducible Protein 10-biomarker for treatment outcome in chronic hepatitis C

被引：0
|
作者：
Sultana, Camelia [1 ,2 ]
Oprisan, Gabriela [3 ]
Grancea, Camelia [2 ]
Teleman, Monica Delia [4 ]
Oprea, Cristiana [5 ]
Florescu, Simin [5 ]
Dinu, Sorin [3 ]
Ceausu, Emanoil [5 ]
Ruta, Simona [1 ,2 ]
机构：
[1] Carol Davila Univ Med & Pharm, Virol Discipline, 8 Eroilor Sanit Bvd, Bucharest, Romania
[2] Stefan S Nicolau Inst Virol, Dept Emergent Viral Dis, 285 Mihai Bravu Bvd, Bucharest, Romania
[3] NIRDMI Cantacuzino, Mol Epidemiol Lab, 103 Splaiul Independentei Bvd, Bucharest, Romania
[4] Carol Davila Univ Med & Pharm, Dept Microbiol & Epidemiol, Bucharest, Romania
[5] Dr Victor Babes Clin Infect & Trop Dis, 281 Mihai Bravu Bvd, Bucharest, Romania
来源：
ROMANIAN BIOTECHNOLOGICAL LETTERS | 2017年 / 22卷 / 06期
关键词：
chronic hepatitis C; treatment; IP-10; sCD26; IL28B polymorphism; HCV INFECTION; FIBROSIS; PREDICTS; CXCL10; IL28B; INFLAMMATION; RNA;
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The predictive value of two easy-to-determine serum biomarkers: IP-10 (Interferon-gamma inducible protein-10 kD) and sCD26 (soluble CD26) on the virological response of interferon-based therapy was assessed in 119 patients with chronic hepatitis C. Patients who obtained sustained virological response (SVR) had significantly decreased baseline IP-10 concentrations as compared to non-responders (mean IP-10 = 338 +/- 200 pg/mL vs. 472.7 +/- 254 g/mL; p=0.003). Correlation of this inexpensive serological marker with IL2B genotype and baseline HCV viral load can be used in the selection of patients who might benefit from interferon-based therapies, which are currently available in developing economies. On the contrary, there was no correlation between the baseline concentration of sCD26 and the outcome of treatment. IP-10 might be a suitable biomarker to predict virological success after pegylated interferon alpha and ribavirin treatment.
引用
收藏
页码：13155 / 13162
页数：8
相关论文
共 50 条
  • [1] Association of interferon-gamma inducible protein 10 polymorphism with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B
    Limothai, Umaporn
    Chuaypen, Natthaya
    Khlaiphuengsin, Apichaya
    Posuwan, Nawarat
    Wasitthankasem, Rujipat
    Poovorawan, Yong
    Tangkijvanich, Pisit
    ANTIVIRAL THERAPY, 2016, 21 (02) : 97 - 106
  • [2] Pretreatment serum interferon gamma inducible protein-10 as biomarker of fibrosis and predictor of virological response in genotype 4 hepatitis C virus infection
    Khalifa, K. A.
    Radwan, W. M.
    Attallah, K. M.
    Hosney, H.
    Eed, E. M.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2014, 77 (04): : 401 - 407
  • [3] Interferon-gamma, interleukin-18, monokine induced by interferon-gamma and interferon-gamma-inducible protein-10 in histiocytic necrotizing lymphadenitis
    Ohshima, K
    Haraoka, S
    Takahata, Y
    Takada, H
    Tsutiya, K
    Suzuki, K
    Suzumiya, J
    Kikuchi, M
    LEUKEMIA & LYMPHOMA, 2002, 43 (05) : 1115 - 1120
  • [4] Interleukin-28B polymorphisms and interferon gamma inducible protein-10 serum levels in seronegative occult hepatitis C virus infection
    Bartolome, Javier
    Castillo, Inmaculada
    Antonio Quiroga, Juan
    Carreno, Vicente
    JOURNAL OF MEDICAL VIROLOGY, 2016, 88 (02) : 268 - 274
  • [5] Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients
    Wang, Yadong
    Zhao, Caiyan
    Zhang, Li
    Yu, Weiyan
    Shen, Chuan
    Wang, Wei
    Zhen, Zhen
    Zhou, Junying
    ANTIVIRAL RESEARCH, 2014, 103 : 51 - 59
  • [6] Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy
    Nishikawa, Hiroki
    Enomoto, Hirayuki
    Nasu, Akihiro
    Aizawa, Nobuhiro
    Saito, Masaki
    Tamori, Akihiro
    Kawada, Norifumi
    Kimura, Toru
    Osaki, Yukio
    Nishiguchi, Shuhei
    HEPATOLOGY RESEARCH, 2014, 44 (14) : E397 - E407
  • [7] Transdiagnostic Associations between Anger Hostility and Chemokine Interferon-gamma Inducible Protein 10
    Soloey-Nilsen, Hedda
    Nygaard-Odeh, Kristin
    Kristiansen, Magnhild Gangsoey
    Kvig, Erling Inge
    Brekke, Ole Lars
    Mollnes, Tom Eirik
    Berk, Michael
    Reitan, Solveig Klaebo
    Oiesvold, Terje
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2024, 22 (02) : 285 - 294
  • [8] Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: A case-control study
    Alsleben, Neele
    Ruhwald, Morten
    Ruessmann, Holger
    Marx, Florian M.
    Wahn, Ulrich
    Magdorf, Klaus
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2012, 44 (04) : 256 - 262
  • [9] The Impact of Interferon-gamma (IFN-gamma) and IFN-gamma-Inducible Protein 10 (IP-10) Genes' Polymorphism on Risk of Hepatitis C Virus-Related Liver Cirrhosis
    Talaat, Roba M.
    Elsharnoby, Shimaa
    Abdelkhalek, Mohamed S.
    El-Shenawy, Soha Z.
    Elmasry, Samir
    IMMUNOLOGICAL INVESTIGATIONS, 2022, 51 (03) : 688 - 704
  • [10] Interferon gamma and interferon gamma inducible protein-10 in detecting tuberculosis infection
    Kabeer, Basirudeen Syed Ahamed
    Paramasivam, Paulkumaran
    Raja, Alamelu
    JOURNAL OF INFECTION, 2012, 64 (06) : 573 - 579
12345